A handful of companies received a green light from the FDA last year to launch devices intended to treat metabolic disorders, including obesity and type 2 diabetes, and several other technologies are in various stages of development. One of the most interesting aspects of this competitive market is the wide array of approaches these companies are taking to treat this patient population.

PARIS – The wave of mergers and acquisitions in medical technologies that is reshaping the industry could be seen in the shuffling of brand names on the exhibition floor at EuroPCR, the largest European meeting for interventional cardiologists.